Summary by Moomoo AI
In mid-2024, the Qiming Medical-B (VENUS MEDTECH-B) report showed that the company's income and gross profit both decreased by 9.7% compared to the same period last year. The loss during the period decreased by 43%, and the loss attributable to the owners of the parent company decreased by 41%. The company continues to focus on the structural heart disease field, advancing the clinical progress of core pipeline, actively responding to market changes, and pursuing a balance between market share and commercial profit margins. During the reporting period, the company maintained a leading position in the domestic market in the TAVR field, while further increasing its market share and influence in overseas markets. The company is also committed to improving operational efficiency, reducing costs, and did not distribute any dividends.
